ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

3:00PM-4:30PM: Abstract Number: 2225

Physical Inactivity Is Associated with Increased Expression of T Cell Inflammatory Genes in Systemic Lupus

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes III: Genetic Factors

3:00PM-4:30PM: Abstract Number: 2195

Pre-exposure Prophylaxis for SARS-CoV-2 with Subcutaneous Casirivimab/Imdevimab in Vaccine-refractory Patients with Immune-mediated Inflammatory Diseases

Abstracts: Epidemiology and Public Health II: COVID, Infection and Pregnancy Outcomes

3:00PM-4:30PM: Abstract Number: 2199

Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data

Abstracts: Health Services Research

3:00PM-4:30PM: Abstract Number: 2220

Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patients Receiving JAK Inhibitors in South Korea: A Nationwide Population-based Study

Abstracts: RA – Treatment III: Comorbidities and Consequences

3:00PM-4:30PM: Abstract Number: 2215

Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis

Abstracts: RA – Treatment III: Comorbidities and Consequences

3:00PM-4:30PM: Abstract Number: 2200

Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare

Abstracts: Health Services Research

3:00PM-4:30PM: Abstract Number: 2196

Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System

Abstracts: Epidemiology and Public Health II: COVID, Infection and Pregnancy Outcomes

3:00PM-4:30PM: Abstract Number: 2192

Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability

Abstracts: Epidemiology and Public Health II: COVID, Infection and Pregnancy Outcomes

3:00PM-4:00PM: Abstract Number: 2179

Spatial and Single-Cell Transcriptomics Identify Alcam+ Macrophage / CD6+ T-Cell Interactions and Accumulation of IgG2b+ Class-Switched Plasma Cells in Marco+ Medullary Sinuses of Joint-Draining Popliteal Lymph Nodes in TNF-Tg Mice with Advanced Arthritis

Abstracts: RA – Animal Models

3:00PM-4:30PM: Abstract Number: 2207

Structural Ultrasound Features of Joints and Tendons of Healthy Children: Development of Normative Data

Abstracts: Imaging of Rheumatic Diseases

3:00PM-4:00PM: Abstract Number: 2188

The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial

Abstracts: Cognition and Behavior in RA and Systemic Sclerosis

3:00PM-4:30PM: Abstract Number: 2221

The Molecular Endotypes of Type 1 and Type 2 SLE

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes III: Genetic Factors

3:00PM-4:30PM: Abstract Number: 2219

Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Abstracts: RA – Treatment III: Comorbidities and Consequences

3:00PM-4:30PM: Abstract Number: 2223

Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes III: Genetic Factors

3:00PM-4:00PM: Abstract Number: 2180

Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner

Abstracts: RA – Animal Models

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].